C-ZYAERockfish Bio
senolytics, IAAC-based therapies, mRNA-based therapies
clearingrna therapeutic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-ZYAE
C-ZYAEC-ZYAEsenolytics, IAAC-based therapies, mRNA-based therapies
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Rockfish Bio senolytics, IAAC-based therapies, mRNA-based therapies
Rockfish Bio is developing senolytic drug candidates that specifically target and remove senescent cells. The company describes applications across age-related diseases including chronic kidney disease, diabetes, cardiovascular diseases, liver fibrosis, neurodegenerative diseases, sarcopenia, immunosenescence, lung diseases, osteoarthritis, and frailty. Its lead compound RFB01016 is described as extending health and life span, improving neuromuscular function, and reducing senescent cells in several tissues in preclinical studies.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Rockfish Bio — Early mechanism · Bottom quartile. Derived deterministically from 4 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic